The Taiwan Futures Exchange (TAIFEX) yesterday said that heavy losses sustained by investors during a bout of volatility last week were the result of a lack of sound risk management and not caused by flaws in its trading mechanism.
Reacting to a steep overnight drop in the Dow Jones Industrial Average, the TAIEX tumbled 4.95 percent, or 542.25 points, to close at 10,404 on Wednesday last week.
During the session, a number of TAIEX options investors caught in the stampede following the market rout were left with especially heavy losses, which they said could have been avoided.
Bearish investors who had sold call options said that prices of their positions had climbed higher, bucking the TAIEX’s decline.
Affected investors also said that negligent market makers had prevented them from settling their positions to minimize losses.
They also questioned the TAIFEX’s decision to exclude the options market from its price stabilization measures.
The TAIEX said that abnormal options price movements during the session were caused by a spike in volatility and were fanned by futures brokerages that had proceeded to force the settlement of positions held by customers in a bid to prevent further losses as their portfolio value tanked.
Most of the affected investors had options positions that were deeply out of the money or had a further-out expiry date, the TAIFEX said, adding that market makers are only obligated to provide more immediate options contracts.
The exchange said that its price stabilization mechanism is designed to guard against market disruptions from sudden occurrences, such as “fat finger” errors, and that it does not regulate continued price actions.
Price stabilization measures implemented by futures authorities in Hong Kong also do not include the options market, it added.
The Chinese National Futures Association (CNFA, 期貨公會) said that when brokerages force settlement of customers’ positions, the action is aimed at containing risk and is carried out automatically once the required conditions are met.
In this case, futures brokerages are not required to anticipate market movements and find the most favorable trades for their customers, the association said, reminding investors that the options market is a zero-sum game.
Investors had complained that positions were settled at the worst possible price points, during the stampede, while others said that brokerages had ignored that they had combination positions — a trading strategy that involves the purchase and sale of call and put options on the same underlying asset.
The TAIFEX estimated that investors had failed to settle a total of NT$120 million (US$4.1 million) from the session alone.
Futures brokerages said that they had taken collateral and arranged repayment plans with most of the affected investors.
UPGRADE AND TRANSFORM: Although the cross-strait trade deal might remain, the Ministry of Economic Affairs said businesses should prepare for any disruptions Taiwan might face a decline in foreign trade with China if the cross-strait Economic Cooperation Framework Agreement (ECFA) ends this year, Minister of Economic Affairs Shen Jong-chin (沈榮津) said yesterday. The agreement, which was signed and put into effect in 2010 to reduce trade barriers across the Taiwan Strait, is expected to end this year, despite not having an exact termination date. “We have not received notification [from China] that it wishes to terminate ECFA,” Shen told reporters prior to attending a meeting at the Legislative Yuan. “Even if we are notified, the agreement would only cease after six months.” While acknowledging the
The Ministry of Economic Affairs yesterday gave the green light to Good Way Technology Co’s (東碩資訊) application to invest up to NT$700 million (US$23.1 million) in Taiwan under a three-year program that provides incentives for overseas Taiwanese companies to invest back home. Good Way, which specializes in docking stations and counts Intel Corp among its major clients, plans to set up a manufacturing facility in New Taipei City’s Sijhih District (汐止), the ministry said in a statement. Good Way, which has a research and development facility in Taiwan and only one manufacturing plant — in Kunshan, China — decided to expand its
Novartis AG chief executive Vas Narasimhan said his Sandoz generics unit’s malaria, lupus and arthritis drug hydroxychloroquine is the company’s biggest hope against COVID-19, Swiss weekly SonntagsZeitung reported yesterday. Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which US President Donald Trump also has been promoting, can be approved for use. Other companies including Bayer AG and Teva Pharmaceutical Industries Ltd have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences Inc is testing its experimental drug remdesivir against COVID-19. “Pre-clinical studies in animals, as well as the first data from clinical
Business sentiment in all industries last month weakened further as the number of COVID-19 infections escalated, threatening to push the global economy into a recession, the Taiwan Institute of Economic Research (TIER, 台經院) said yesterday. The business confidence gauge for local manufacturers fell 5.31 points to 88.73 from a month earlier, the lowest since January last year, a monthly survey by the Taipei-based institute indicated. Only 19.3 percent of manufacturers remained upbeat about their business outlook in the coming six months, 6 percentage points lower from a month earlier, while companies with a gloomy outlook rose 9.8 percentage points to 36.9 percent,